| 13.36 0.54 (4.21%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.45 |
1-year : | 20.38 |
| Resists | First : | 14.94 |
Second : | 17.45 |
| Pivot price | 12.05 |
|||
| Supports | First : | 12.61 |
Second : | 11.17 |
| MAs | MA(5) : | 12.32 |
MA(20) : | 12.27 |
| MA(100) : | 13.51 |
MA(250) : | 11.35 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 66.4 |
D(3) : | 46.1 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 16.32 | Low : | 3.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CTNM ] has closed Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.67 - 13.73 | 13.73 - 13.78 |
| Low: | 12.65 - 12.71 | 12.71 - 12.76 |
| Close: | 13.27 - 13.37 | 13.37 - 13.47 |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Tue, 23 Jun 2026
Contineum Therapeutics Inc (CTNM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mon, 01 Jun 2026
Contineum Therapeutics CSO Daniel Lorrain sells $54,862 in stock - Investing.com
Mon, 01 Jun 2026
Contineum Therapeutics (CTNM) CSO sells 4,170 shares under 10b5-1 plan - Stock Titan
Mon, 25 May 2026
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Yahoo Finance
Sun, 17 May 2026
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 15, 2026 - BioSpace
Fri, 08 May 2026
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 93.9 (%) |
| Shares Short | 1,430 (K) |
| Shares Short P.Month | 1,610 (K) |
| EPS | -1.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.2 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -6.89 |
| PEG Ratio | 0 |
| Price to Book value | 1.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|